PMID- 36278154
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221025
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: A 
      systematic review and network meta-analysis.
PG  - 955925
LID - 10.3389/fphar.2022.955925 [doi]
LID - 955925
AB  - Purpose: To perform a systematic review and network meta-analysis to compare the 
      efficacy and safety of currently available docetaxel-based systemic triplet 
      therapies for metastatic hormone-sensitive prostate cancer (mHSPC). Methods: We 
      searched for eligible publications in PubMed, Embase, and Cochrane CENTRAL. 
      Improvements in overall survival (OS) and radiographic progression-free time 
      (rPFS) were compared indirectly using network meta-analysis and evaluated using 
      the surface under the cumulative ranking curve (SUCRA). Other secondary 
      endpoints, such as time to castration-resistant prostate cancer and/or adverse 
      events (AEs), were also compared and evaluated. Results: Five trials were 
      selected and analyzed using a network meta-analysis. Compared to androgen 
      deprivation therapy (ADT) plus docetaxel, darolutamide (hazard ratio [HR]: 0.68, 
      95% credible interval [CrI]: 0.57-0.80) and abiraterone (HR: 0.75, 95% CrI: 
      0.59-0.95) triplet therapy had significantly longer OS, and darolutamide triplet 
      therapy was the first treatment ranked. Abiraterone (HR: 0.49, 95% CrI: 
      0.39-0.61) and enzalutamide (HR: 0.52, 95% CrI: 0.30-0.89) had significantly 
      better rPFS than ADT plus docetaxel; however, all three therapies, including 
      abiraterone, apalutamide, and enzalutamide, were the best options with a similar 
      SUCRA. At most secondary endpoints, systemic triplet therapy was superior to ADT 
      plus docetaxel. The risk of any AEs in darolutamide or abiraterone triplet 
      therapy was comparable with ADT plus docetaxel (odds ratio [OR]: 2.53, 95% 
      credible interval [CrI]: 0.68-12.63; OR: 1.07, 95% CrI: 0.03-36.25). Abiraterone 
      triplet therapy had an increased risk of grade>/=3 AEs (OR: 1.56, 95% CrI: 
      1.15-2.11). Conclusion: Systemic triplet therapy was more effective than ADT plus 
      docetaxel for mHSPC. Of the triplet therapy regimens, darolutamide ranked first 
      in terms of improved OS. Abiraterone and enzalutamide triplet ranked first in 
      terms of rFPS, however, it did not confer a statistically difference among all 
      triplet regimens. The overall risk of AEs was comparable. More studies are 
      required for current and potential combinations of systemic triplet therapy.
CI  - Copyright (c) 2022 Jian, Zhan, Hu, He, Chen, Hu and Lu.
FAU - Jian, Tengteng
AU  - Jian T
AD  - Department of Urology, The First Hospital of Jilin University, Changchun, China.
FAU - Zhan, Yang
AU  - Zhan Y
AD  - School of Life Sciences, Jilin University, Changchun, China.
FAU - Hu, Kebang
AU  - Hu K
AD  - Department of Urology, The First Hospital of Jilin University, Changchun, China.
FAU - He, Liang
AU  - He L
AD  - Department of Urology, The First Hospital of Jilin University, Changchun, China.
FAU - Chen, Sunmeng
AU  - Chen S
AD  - Department of Urology, The First Hospital of Jilin University, Changchun, China.
FAU - Hu, Rui
AU  - Hu R
AD  - Department of Urology, The First Hospital of Jilin University, Changchun, China.
FAU - Lu, Ji
AU  - Lu J
AD  - Department of Urology, The First Hospital of Jilin University, Changchun, China.
LA  - eng
PT  - Systematic Review
DEP - 20221006
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9582339
OTO - NOTNLM
OT  - Docetaxel
OT  - metastatic hormone-sensitive prostate cancer
OT  - network meta-analysis
OT  - systemic therapy
OT  - triplet therapy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/25 06:00
MHDA- 2022/10/25 06:01
PMCR- 2022/10/06
CRDT- 2022/10/24 04:45
PHST- 2022/05/29 00:00 [received]
PHST- 2022/09/21 00:00 [accepted]
PHST- 2022/10/24 04:45 [entrez]
PHST- 2022/10/25 06:00 [pubmed]
PHST- 2022/10/25 06:01 [medline]
PHST- 2022/10/06 00:00 [pmc-release]
AID - 955925 [pii]
AID - 10.3389/fphar.2022.955925 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Oct 6;13:955925. doi: 10.3389/fphar.2022.955925. 
      eCollection 2022.